Every 8-K that Tectonic Therapeutic, Inc. (TECX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TECX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TECX filings page.
Tectonic Therapeutic, Inc. (TECX) announced favorable topline safety, tolerability and pharmacokinetic results for TX2100 in its Phase 1a trial in healthy volunteers and said the study met its primary objectives. Detailed safety, tolerability, pharmacokinetic and anti-drug antibody results are to be presented at the CureHHT conference October 12–16, 2026.
The FDA granted TX2100 Fast Track Designation for HHT in September 2026, after clearing the company’s IND application in August 2026 for a U.S. Phase 1b trial. Two HHT patient studies are planned to run in parallel: an open-label Phase 1b trial in patients dependent on hematologic support, anticipated to start by year-end 2026, and a placebo-controlled Phase 2 trial in moderate-to-severe HHT patients, anticipated to start in early 2027. Phase 1b endpoints explore iron and red blood cell support needs and hematologic parameters; Phase 2 endpoints are expected to include epistaxis, hemoglobin and hematologic support.
Tectonic Therapeutic, Inc. reported financial results for the quarter and six months ended June 30, 2026 and highlighted progress in its clinical pipeline. Enrollment in the global APEX Phase 2 trial of TX45 in PH-HFpEF was completed, with topline results expected in early Q1 2027. The company also completed dosing of single-dose cohorts in the TX2100 Phase 1a trial; subject to favorable data, it plans Phase 1b and Phase 2 studies in hereditary hemorrhagic telangiectasia.
For Q2 2026, research and development expense was $18,048 thousand and general and administrative expense was $6,170 thousand, for total operating expenses of $24,218 thousand. Net loss was $22,285 thousand, or $1.18 per share, compared with $19,984 thousand, or $1.07 per share, a year earlier. For the first six months of 2026, net loss was $47,526 thousand. As of June 30, 2026, cash and cash equivalents were $227,068 thousand, total assets were $237,034 thousand, and stockholders’ equity was $223,846 thousand.
Tectonic Therapeutic, Inc. reported results from its 2026 Annual Meeting and a key clinical milestone. Stockholders elected Timothy A. Springer and Stefan Vitorovic as Class II directors, with up to 13.9 million votes for each candidate, and ratified Deloitte & Touche LLP as independent auditor with 17,225,948 votes for and minimal opposition. Stockholders also approved, on an advisory basis, executive compensation with 14,292,497 votes in favor.
The company announced completion of enrollment in APEX, its 24‑week, global Phase 2 trial of TX45 in pulmonary hypertension associated with heart failure with preserved ejection fraction (PH‑HFpEF). APEX enrolled 191 patients across 14 countries, including 137 with the more severe combined pre‑ and post‑capillary pulmonary hypertension (CpcPH) and pulmonary vascular resistance above 3 Wood Units. Tectonic plans to report topline APEX results in early Q1 2027.
Tectonic Therapeutic, Inc. reported first quarter 2026 results and updated progress on its clinical pipeline. The company ended March 31, 2026 with cash and cash equivalents of $236.9 million, which it expects will fund operations into Q4 2028, including Phase 2 readouts for TX45 in PH-HFpEF and PH-ILD and continued development of TX2100 for HHT.
Research and development expenses rose to $20.9 million from $13.0 million a year earlier, and general and administrative expenses increased to $6.4 million from $5.3 million. Net loss widened to $25.2 million from $15.9 million, reflecting heavier investment in clinical trials and personnel.
Clinically, TX45’s APEX Phase 2 trial in PH-HFpEF is ongoing with topline data expected in late Q4 2026 or early Q1 2027, while the ALPINE Phase 2 trial in PH-ILD has begun enrollment. TX2100 advanced into a Phase 1a trial in healthy volunteers, with topline data expected by the end of Q3 2026 and a Phase 2 HHT study planned for early 2027.
Tectonic Therapeutic, Inc. appointed Jessica Chutter to its Board of Directors and Audit Committee, effective as of the company’s 2026 annual stockholder meeting, described in the press release as June 8, 2026. She will serve as a Class III director with a term expiring at the 2027 annual meeting and has been determined to be an independent director under Nasdaq rules.
As a non-employee director, Ms. Chutter is eligible for an annual cash retainer of $40,000 for Board service and $7,500 for Audit Committee service, plus a one-time option grant for 20,400 shares under the 2024 Equity Incentive Plan. The initial option vests over three years, and future annual option grants are expected after each stockholder meeting, with vesting tied to continued Board service and accelerated vesting upon a qualifying change in control.
Tectonic Therapeutic, Inc. reported a larger net loss as it ramped R&D to advance two lead programs while strengthening its balance sheet. For the quarter ended December 31, 2025, net loss was $19.2 million, versus $12.4 million a year earlier, with research and development expenses rising to $16.3 million from $9.2 million. Full-year 2025 net loss was $74.2 million.
Cash and cash equivalents reached $253.8 million as of December 31, 2025, up from $141.2 million a year earlier, and are expected to fund operations into Q4 2028, including Phase 2 readouts for TX45 and development of TX2100. TX45 delivered positive Phase 1b data in Group 2 pulmonary hypertension, showing a 29.2% reduction in pulmonary capillary wedge pressure and a 17.3% improvement in cardiac output, and has moved into multiple Phase 2 trials. TX2100 entered a Phase 1a trial in healthy volunteers in February 2026 targeting hereditary hemorrhagic telangiectasia.
Tectonic Therapeutic, Inc. is expanding and reshaping its board leadership while advancing its lead bleeding-disorder program TX2100. The board increased its size from six to seven directors and appointed industry veteran François Nader, M.D. as an independent Class III director, effective April 1, 2026, when he will also become Chair of the Board.
Current Chair Terry McGuire will step down as Chair on April 1, 2026 and remain a director until the 2026 annual stockholder meeting. As a non-employee director and Chair, Dr. Nader will receive cash retainers and an option to purchase 20,400 shares, with additional annual equity in line with the company’s compensation policy. Tectonic also highlighted TX2100, a potential first-in-class APJ antagonist for hereditary hemorrhagic telangiectasia, now in an ongoing Phase 1a trial in healthy volunteers, with Phase 1b and Phase 2 studies planned.
Tectonic Therapeutic, Inc. filed a current report to note that it announced financial results for the quarter ended September 30, 2025 and shared a general business update on November 6, 2025. These details are contained in a press release furnished as an exhibit to the report.
Tectonic Therapeutic (TECX) reported a communications update. The company posted a presentation titled “TX45 Phase 1b (Part B) PH-HFrEF Data Release Single Dose Hemodynamic Trial” and issued a press release announcing positive topline data from the Phase 1b Part B clinical trial of TX45 in patients with Group 2 pulmonary hypertension in HFrEF.
The presentation is furnished as Exhibit 99.1, and the press release is furnished as Exhibit 99.2 and, other than the quotes contained therein, is incorporated by reference. No financial results or transaction terms were disclosed in this update.